AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans
AlphaTON (Nasdaq: ATON) and its oncology subsidiary Cyncado Therapeutics announced a non-binding Letter of Intent with Australia’s Asbestos and Dust Diseases Research Institute (ADDRI) to run an investigator-initiated trial of TT-4, a selective A2B receptor antagonist, in mesothelioma on Nov 12, 2025.
The ADDRI-sponsored study is planned to enroll approximately 50 patients, will be led by A/Prof Steven Kao and Dr Melvin Chin, and will run alongside Cyncado’s planned U.S. mesothelioma activities, subject to a definitive agreement and customary approvals. Cyncado will provide TT-4 and limited support. The trial targets second-line/after first-line settings where options remain limited.
AlphaTON (Nasdaq: ATON) e la sua subsidiary oncologica Cyncado Therapeutics hanno annunciato una lettera di intenti non vincolante con l'Asbestos and Dust Diseases Research Institute (ADDRI) dell'Australia per condurre uno studio promosso da un ricercatore su TT-4, un antagonista selettivo del recettore A2B, nel mesotelioma, il 12 novembre 2025.
Lo studio sponsorizzato dall'ADDRI prevede di arruolare circa 50 pazienti, sarà guidato dal Prof. Steven Kao e dal Dr Melvin Chin, e si svolgerà parallelamente alle attività mesotelioma statunitensi pianificate da Cyncado, soggette a un accordo definitivo e alle autorizzazioni consuete. Cyncado fornirà TT-4 e supporto limitato. Lo studio si propone per contesti di seconda linea/dopo la prima linea in cui le opzioni sono limitate.
AlphaTON (Nasdaq: ATON) y su filial oncológica Cyncado Therapeutics anunciaron una carta de intenciones no vinculante con el Asbestos and Dust Diseases Research Institute (ADDRI) de Australia para realizar un ensayo iniciado por investigadores de TT-4, un antagonista selectivo del receptor A2B, en mesotelioma, el 12 de noviembre de 2025.
El estudio patrocinado por ADDRI está previsto para inscribir aproximadamente 50 pacientes, será liderado por el Prof. A/Steven Kao y el Dr. Melvin Chin, y se llevará a cabo junto a las actividades de mesotelioma en Estados Unidos planificadas por Cyncado, sujeto a un acuerdo definitivo y a las aprobaciones habituales. Cyncado proporcionará TT-4 y apoyo limitado. El ensayo se enfoca en escenarios de segunda línea/después de la primera línea donde las opciones siguen siendo limitadas.
AlphaTON (나스닥: ATON) 및 그 종양학 자회사인 Cyncado Therapeutics는 호주 ADDRI(Asbestos and Dust Diseases Research Institute)와 비구속적 의향서(Letter of Intent)를 발표했습니다. TT-4는 선택적 A2B 수용체 길항제로, 중피종에서의 연구자 주도 시험을 진행하려고 하며 날짜는 2025년 11월 12일입니다.
ADDRI가 후원하는 연구는 약 50명 환자를 모집할 예정이며, 스티븐 Kao 교수(A/Prof)와 멜빈 진 박사(Dr Melvin Chin)가 이끌고, Cyncado의 미국 내 중피종 활동 계획과 함께 진행될 예정이며 확정 계약 및 일반 승인에 따릅니다. Cyncado는 TT-4를 제공하고 제한적인 지원을 할 것입니다. 이 임상은 2차 라인/1차 라인 이후의 선택지가 제한된 상황을 목표로 합니다.
AlphaTON (Nasdaq: ATON) et sa filiale oncologique Cyncado Therapeutics ont annoncé une lettre d'intention non contraignante avec l'Institut australien de recherche sur les maladies liées à l'amiante et à la poussière (ADDRI) pour mener un essai initié par les investigateurs de TT-4, un antagoniste sélectif du récepteur A2B, dans le mésothélome, le 12 novembre 2025.
L'étude sponsorisée par l'ADDRI prévoit d'enregistrer environ 50 patients, sera dirigée par le Professeur Steven Kao et le Dr Melvin Chin, et se déroulera parallèlement aux activités américaines prévues par Cyncado sur le mésothéliome, sous réserve d'un accord définitif et des autorisations habituelles. Cyncado fournira TT-4 et un soutien limité. L'essai vise les situations de seconde ligne/ après la première ligne où les options restent limitées.
AlphaTON (Nasdaq: ATON) und seine Onkologie-Tochtergesellschaft Cyncado Therapeutics gaben eine unverbindliche Absichtserklärung mit dem australischen ADDRI (Asbestos and Dust Diseases Research Institute) bekannt, um eine vom Forscher initiierte Studie von TT-4, einem selektiven Antagonisten des A2B-Rezeptors, beim Mesotheliom durchzuführen, am 12. November 2025.
Die von ADDRI geförderte Studie soll ca. 50 Patienten einschließen, wird von A/Prof Steven Kao und Dr. Melvin Chin geleitet und parallel zu Cyncados geplanten US-Mesotheliom-Aktivitäten laufen, vorbehaltlich einer definitiven Vereinbarung und üblicher Genehmigungen. Cyncado wird TT-4 bereitstellen und begrenzte Unterstützung leisten. Die Studie richtet sich an Zweite-Line-/Nach der ersten Linie Settings, in denen die Optionen begrenzt sind.
ألفاTON (ناسداك: ATON) وشركةها الفرعية في الأورام Cyncado Therapeutics أعلنوا عن رسالة نوايا غير ملزمة مع معهد أبحاث أمراض الأسبست والغبار (ADDRI) في أستراليا لإجراء تجربة يقودها باحث بمبادرة ADDRI لـ TT-4، وهو مضاد انتقائي لمستقبل A2B، في الورم البلّّي (المِّسْتُوثُيولِيوم) في 12 نوفمبر 2025.
الدراسة التي ترعاها ADDRI مُزمع أن تسجّل نحو 50 مريضاً، وستقودها الأستاذ/الدكتور Steven Kao والدكتور Melvin Chin، وستجري بالتوازي مع أنشطة الورم البلّي الأمريكية المخطط لها من قبل Cyncado، رهناً باتفاق نهائي والموافقات المعتادة. ستوفر Cyncado TT-4 ودعماً محدوداً. تستهدف التجربة حالات الخط الثاني/بعد الخط الأول حيث تظل الخيارات محدودة.
- None.
- None.
Insights
ADDRI and Cyncado plan a 50‑patient investigator‑initiated mesothelioma trial of TT‑4, expanding an international clinical program.
AlphaTON’s oncology subsidiary will supply TT‑4 and limited support under a non‑binding LOI to an ADDRI‑sponsored investigator‑initiated trial planned to enroll about 50 patients, led by A/Prof Steven Kao and Dr Melvin Chin. This creates a parallel Australian arm to Cyncado’s planned U.S. mesothelioma activities and aims to generate decision‑quality clinical data on TT‑4, a selective A2B receptor antagonist.
The near‑term value depends entirely on trial initiation, enrollment pace, and the protocol’s endpoints; the announcement itself does not report clinical results, regulatory approvals, or financial terms. Key risks include reliance on a definitive agreement and customary approvals, potential delays in site start‑up or recruitment, and limits of IIT resources compared with company‑led studies.
Watch for a signed definitive agreement, ethics/regulatory approvals, the trial protocol (primary endpoint and inclusion criteria), and first patient in and enrollment milestones over the next 6–18 months; these items will determine whether the program yields actionable data to complement U.S. plans.
ADDRI-sponsored trial in Australia planned to enroll approximately 50 patients, led by A/Prof Steven Kao and Dr Melvin Chin; part of Cyncado’s international program for mesothelioma
Dover, DE and Sydney, Australia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today announced a non-binding Letter of Intent (LOI) between Australia’s Asbestos and Dust Diseases Research Institute (ADDRI) and Tarus Therapeutics, LLC to conduct an investigator-initiated clinical trial evaluating TT-4, Cyncado’s selective A2B receptor antagonist, in mesothelioma. The Australian trial is planned to enroll approximately 50 patients and will be run in addition to Cyncado’s U.S. mesothelioma activities, subject to a definitive agreement and customary approvals.
Highlights
- ADDRI to sponsor an investigator-initiated clinical trial of TT-4 in mesothelioma in Australia (planned enrollment of 50 patients)
- Addresses the urgent need after first-line therapy, where there is no widely accepted second-line standard and outcomes remain poor
- Builds on previously shared preclinical findings supporting evaluation of TT-4 in mesothelioma
- Cyncado to provide TT-4 and limited support under a definitive agreement
- Part of an international program running alongside Cyncado’s planned U.S. activities
- Led by A/Prof Steven Kao (Chris O’Brien Lifehouse/ADDRI) and Dr Melvin Chin (Sir Charles Gairdner Hospital/NCARD)
“ADDRI’s leadership in asbestos-related disease makes Australia a compelling setting for a TT-4 investigator-initiated trial,” said Peter Molloy, Chief Executive Officer, Cyncado Therapeutics. “We are building an international mesothelioma program to move quickly, generate decision-quality data, and bring better options closer to patients.”
“We exist to improve outcomes for people living with asbestos and dust-related diseases,” said Kim Brislane, Chief Executive Officer, ADDRI. “Australia faces a significant mesothelioma burden. An IIT lets our clinical community evaluate A2B antagonism through a rigorous, patient-focused protocol, and contribute high-quality data that can inform care in Australia and abroad.”
About the Investigators
A/Prof Steven Kao (Chris O’Brien Lifehouse / ADDRI) - Thoracic medical oncologist and mesothelioma specialist who oversees trials at Chris O’Brien Lifehouse; ADDRI research fellow with a PhD focused on mesothelioma; principal investigator on multiple mesothelioma studies and co-author of peer-reviewed work on biomarkers and treatment response.
Dr Melvin Chin (Sir Charles Gairdner Hospital / NCARD) - Clinician-scientist in Western Australia dedicated to mesothelioma care and research; leads and recruits for thoracic oncology trials across the WA network; active NCARD investigator on blood-based biomarkers and immunotherapy response; frequent contributor to peer-reviewed mesothelioma publications.
Mesothelioma at a glance
Mesothelioma is an aggressive, asbestos-linked cancer with poor prognosis: IO has improved first-line outcomes, but most patients relapse. There’s no established second-line standard, making clinical trials a priority, particularly in Australia, which has one of the highest per-capita burdens.
About the Asbestos and Dust Diseases Research Institute (ADDRI)
ADDRI is an independent, not-for-profit research institute based at Concord Hospital, Sydney, committed to reducing and ultimately eliminating the impact of asbestos and dust-related diseases. ADDRI is the World Health Organization Collaborating Centre for the Elimination of Asbestos-Related Diseases, supporting research, prevention and patient services in Australia and internationally.
About AlphaTON Capital Corp
AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The Company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company.
Led by Chief Executive Officer, Brittany Kaiser and Chief Investment Officer, Enzo Villani, the company's activities span network validation and staking operations, development of Telegram-based applications, and potential strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications. AlphaTON Capital is incorporated in the British Virgin Islands and trades on Nasdaq under the ticker symbol ATON.
AlphaTON Capital, through its legacy business, is also advancing potentially first-in-class therapies that target known checkpoint resistance pathways to potentially achieve durable treatment response and improve quality of life for patients. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide development of novel immunotherapy assets and asset combinations.
About Cyncado Therapeutics
Tarus Therapeutics, LLC (operating as Cyncado Therapeutics), a clinical stage, wholly owned subsidiary of AlphaTON Capital Corp, is developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology. The Company's lead program, TT-4, is an oral, ultra-selective A2B receptor antagonist with an initial focus on mesothelioma, advancing toward first-patient dosing in Q1 2026. Cyncado is also developing dual-antagonist strategies designed to achieve comprehensive blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company's business strategy, plans and objectives, future operations, clinical development timelines, TON ecosystem growth, therapeutic development outcomes, regulatory approvals, and statements preceded by, followed by, or including words such as "believe," "expects," "anticipates," "intends," "estimates," "will," "may," "plans," "potential," "targets," or similar expressions, are forward-looking statements.
These forward-looking statements are subject to substantial risks and uncertainties, including but not limited to: signing a definitive agreement for and implementing the Australian trial; clinical trial outcomes and regulatory approvals; uncertainty of the Company's investment in TON and digital assets; regulatory and legal risks associated with digital assets; risks related to Telegram's platform and the TON ecosystem; market volatility; competitive risks in both digital assets and therapeutics development; and other factors described in "Item 3 – Key Information-Risk Factors" in the Company's Annual Report on Form 20-F for the year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.
Although the Company believes the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to update publicly or revise any forward-looking statements, except as required by law.
Contact Information
Investor Relations
AlphaTON Capital Corp
AlphaTON@icrinc.com
(203) 682-8200
Media Inquiries
Richard Laermer
RLM PR
AlphaTON@rlmpr.com
(212) 741-5106 X 216
Richard Laermer AlphaTON (at) rlmpr.com
FAQ
What did AlphaTON (ATON) announce about TT-4 on November 12, 2025?
How many patients is the ADDRI-sponsored TT-4 mesothelioma trial planning to enroll?
Who will lead the Australian TT-4 mesothelioma investigator-initiated trial?
Will Cyncado provide drug supply for the ADDRI TT-4 trial in Australia?
Is the ADDRI TT-4 trial in Australia binding and starting immediately?
How does the Australian TT-4 trial relate to Cyncado’s U.S. mesothelioma program?
